Limits...
Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents.

Valdivia-Silva J, Medina-Tamayo J, Garcia-Zepeda EA - Int J Mol Sci (2015)

Bottom Line: Research in this area is progressing rapidly, and development of novel agents based on chemokine/ chemokine receptors antagonist functions are emerging as attractive alternative drugs.Some of these novel agents include generation of chemokine-derived peptides (CDP) with potential agonist and antagonist effects on inflammation, cancer and against bacterial infections.CDP have been generated mainly from N- and C-terminus chemokine sequences with subsequent modifications such as truncations or elongations.

View Article: PubMed Central - PubMed

Affiliation: Chemokine Biology Research Laboratory, Programa Institucional de Investigación en Cancer de Mama, Mexico DF 04510, Mexico.

ABSTRACT
Chemokines are a burgeoning family of chemotactic cytokines displaying a broad array of functions such as regulation of homeostatic leukocyte traffic and development, as well as activating the innate immune system. Their role in controlling early and late inflammatory stages is now well recognized. An improper balance either in chemokine synthesis or chemokine receptor expression contributes to various pathological disorders making chemokines and their receptors a useful therapeutic target. Research in this area is progressing rapidly, and development of novel agents based on chemokine/ chemokine receptors antagonist functions are emerging as attractive alternative drugs. Some of these novel agents include generation of chemokine-derived peptides (CDP) with potential agonist and antagonist effects on inflammation, cancer and against bacterial infections. CDP have been generated mainly from N- and C-terminus chemokine sequences with subsequent modifications such as truncations or elongations. In this review, we present a glimpse of the different pharmacological actions reported for CDP and our current understanding regarding the potential use of CDP alone or as part of the novel therapies proposed in the treatment of microbial infections and cancer.

No MeSH data available.


Related in: MedlinePlus

Chemokine-derived peptides (CDP) as novel tools in anticancer therapy. The figure shows three strategies against tumour biology: (1) induction of migration of antitumoral T cells; (2) inhibition of angiogenesis; and (3) reducing tumour growth, invasion and organ-specific metastasis. TCR = T-cell receptor, * chemokine-derived peptides, CTL: Cytotoxic Lymphocytes.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4490481&req=5

ijms-16-12958-f001: Chemokine-derived peptides (CDP) as novel tools in anticancer therapy. The figure shows three strategies against tumour biology: (1) induction of migration of antitumoral T cells; (2) inhibition of angiogenesis; and (3) reducing tumour growth, invasion and organ-specific metastasis. TCR = T-cell receptor, * chemokine-derived peptides, CTL: Cytotoxic Lymphocytes.

Mentions: Several chemokine-based strategies, such as antagonist or blocking antibodies and/or small peptides, have been used in different in vitro and in vivo experiments against cancer so far. Some preclinical trials have demonstrated strong evidence in reducing tumour growth, deleterious cellular infiltrate, vascularity, and metastasis [93] (Figure 1).


Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents.

Valdivia-Silva J, Medina-Tamayo J, Garcia-Zepeda EA - Int J Mol Sci (2015)

Chemokine-derived peptides (CDP) as novel tools in anticancer therapy. The figure shows three strategies against tumour biology: (1) induction of migration of antitumoral T cells; (2) inhibition of angiogenesis; and (3) reducing tumour growth, invasion and organ-specific metastasis. TCR = T-cell receptor, * chemokine-derived peptides, CTL: Cytotoxic Lymphocytes.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4490481&req=5

ijms-16-12958-f001: Chemokine-derived peptides (CDP) as novel tools in anticancer therapy. The figure shows three strategies against tumour biology: (1) induction of migration of antitumoral T cells; (2) inhibition of angiogenesis; and (3) reducing tumour growth, invasion and organ-specific metastasis. TCR = T-cell receptor, * chemokine-derived peptides, CTL: Cytotoxic Lymphocytes.
Mentions: Several chemokine-based strategies, such as antagonist or blocking antibodies and/or small peptides, have been used in different in vitro and in vivo experiments against cancer so far. Some preclinical trials have demonstrated strong evidence in reducing tumour growth, deleterious cellular infiltrate, vascularity, and metastasis [93] (Figure 1).

Bottom Line: Research in this area is progressing rapidly, and development of novel agents based on chemokine/ chemokine receptors antagonist functions are emerging as attractive alternative drugs.Some of these novel agents include generation of chemokine-derived peptides (CDP) with potential agonist and antagonist effects on inflammation, cancer and against bacterial infections.CDP have been generated mainly from N- and C-terminus chemokine sequences with subsequent modifications such as truncations or elongations.

View Article: PubMed Central - PubMed

Affiliation: Chemokine Biology Research Laboratory, Programa Institucional de Investigación en Cancer de Mama, Mexico DF 04510, Mexico.

ABSTRACT
Chemokines are a burgeoning family of chemotactic cytokines displaying a broad array of functions such as regulation of homeostatic leukocyte traffic and development, as well as activating the innate immune system. Their role in controlling early and late inflammatory stages is now well recognized. An improper balance either in chemokine synthesis or chemokine receptor expression contributes to various pathological disorders making chemokines and their receptors a useful therapeutic target. Research in this area is progressing rapidly, and development of novel agents based on chemokine/ chemokine receptors antagonist functions are emerging as attractive alternative drugs. Some of these novel agents include generation of chemokine-derived peptides (CDP) with potential agonist and antagonist effects on inflammation, cancer and against bacterial infections. CDP have been generated mainly from N- and C-terminus chemokine sequences with subsequent modifications such as truncations or elongations. In this review, we present a glimpse of the different pharmacological actions reported for CDP and our current understanding regarding the potential use of CDP alone or as part of the novel therapies proposed in the treatment of microbial infections and cancer.

No MeSH data available.


Related in: MedlinePlus